Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Claridgeon May 30, 2019 7:35pm

86 Views

Post# 29786981

RE:So far, there's no delays in the Ph. 2b

Given the meticulous planning that this company has accustomed us to, do you sincerely believe that 1 month after this news release below, they would have forgotten something or ran into a unexpected bump???

Why this inability to trust those that have delivered perfection so far?

Theralase Commences Phase II NMIBC Clinical Study

Toronto, Ontario – April 25, 2019,

Kipton Lade, B.Sc., M.Sc., MBA, CEO – Device Division, Theralase stated that, “The Company has focused its engineering resources on upgrading the TLC-3200 medical laser system based on clinical feedback gained in the Company’s successfully completed Phase Ib study. We are excited to introduce this next level technology into the Phase II ACT-NMIBC study.”